Biostage Inc - BSTG stock
OTC Symbol: BSTG
Introduction[edit]
Harvard Apparatus Regenerative Technology, Inc. (OTC: HRGN) is a bioengineering firm working on next-generation esophageal implants. Cellspan technology from the Company mixes a patented, biocompatible scaffold with a patient's cells to generate an esophageal implant that might potentially be utilized to treat pediatric esophageal atresia and other esophageal disorders. These implants have the potential to significantly improve children's and adults' quality of life. [1]
The company was previously known as Biostage, Inc. and traded under the symbol BSTG until the name and symbol change on July 20, 2023.[2]
Esophageal Atresia[edit]
Esophageal Atresia (EA) is a fatal congenital abnormality in which newborns are born with a gap between their esophagus and stomach. EA affects roughly 1 in every 2,500-3,500 live births worldwide.[3]
The patient's esophagus is rebuilt thanks to the Biostage Esophageal Implant.
- It is not an organ transplant from another person.
- It's not a chunk of your intestine or stomach in your chest, as is the case with the most common esophageal cancer therapies today.
- It is not an organ transplant from a pig.
- There is no plastic mesh piece still within your body.[3]
At the Mayo Clinic, the Biostage Esophageal Implant was used to regenerate an esophagus for the first time in a cancer patient. To create the scientific groundwork for employing the Biostage Esophageal Implant to correct birth abnormalities in infants who are born without a complete esophagus, the company has also finished substantial large-animal research.[3]
History[edit]
Biostage was founded in 2012 and is headquartered in Holliston, Massachusetts, United States.[4]
On April 1, 2016, the firm changed its name to Biostage, Inc. and began trading under the Nasdaq ticker "BSTG" after being known as Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART). The company's comprehensive commitment and competence in pioneering the development of bioengineered organ implants for the esophagus, bronchus, and trachea are reflected in the name change. It also disassociates itself from its former parent firm, from which it was spun off in November 2013.[5]
Technology[edit]
Biostage technology has emerged as a result of intensive research and development to maximize the interaction of mesenchymal stem cells placed on a biocompatible scaffold. According to preclinical research, once implanted, the scaffold seeded with the patient's cells signals the stem cell niche to drive the regeneration of a biological structure.[6]
Cell frame technology has the potential to allow for the first individualized approach to organ regeneration. The technique uses a multistep procedure in which stem cells from a simple adipose/fat tissue biopsy are grown and banked before being seeded onto a customized framework that replicates the natural proportions of the organ and is restored. The stem cell-containing scaffold is ready to be implanted after several days in a rotating bioreactor. Cell frame technology is intended to provide the cues required for initiating, guiding, and modifying the regenerative process.[6]
Patent[edit]
Biostage's intellectual property portfolio includes 17 registered patents, the majority of which are in the 'Medical Or Veterinary Science; Hygiene area. It has three registered trademarks, with pharmaceutical, veterinary, and sanitary products being the most prevalent class.[4]
Latest News[edit]
Biostage announced its intention to begin patient recruiting for its first clinical trial in early 2023 on December 23, 2022. [6]
On October 25, 2022, announced the issuance of a US patent that protects the extension of Biostage's technology's use from hollow tubes to patches. Biostage anticipates that this new technology will allow it to treat fistulas (holes), strictures (narrow, wing-like structures), or damage to the esophagus such as gastroesophageal reflux disease, or GERD, as well as damage and disease in other parts of the gastrointestinal tracts such as the stomach and intestine. The Biostage Tissue Patch is the name given to this breakthrough device.[7]
- ↑ Linkedin. Biostage, Inc. Accessed on 12/26/2022.
- ↑ PR Newswire. Biostage, Inc. Changes Name to Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN). July 20, 2023.
- ↑ 3.0 3.1 3.2 Biostage.com. About. Accessed on 12/26/2022.
- ↑ 4.0 4.1 Crunchbase. Biostage. Accessed on 12/26/2022.
- ↑ CISION PR NEWSWIRE. Harvard Apparatus Regenerative Technology Changes Name to Biostage, Inc. March 31, 2016.
- ↑ 6.0 6.1 Biostage Technology. Restoring Organ Function. Accessed on 12/26/2022.
- ↑ Biostage Investor Relations. Press Releases. Accessed on 12/26/2022.
